IRDAI probes Care Health's stock option issue to Saluja

IRDAI revealed that a probe into stock option allotment to Saluja is on in response to a query raised by Rahul Kanoj under the Right to Information Act (RTI) to the insurance regulator. The regulator said in its response, "The information sought is not furnished as the same would impede the process of investigation or apprehension." ET has seen IRDAI's response to the RTI query.

Mumbai: The and of India () is investigating the issuance of in Insurance to , the firm's non-executive chairperson.

Saluja is the executive chairperson of (REL), which owns Care Health.

IRDAI revealed that a probe into stock option allotment to Saluja is on in response to a query raised by Rahul Kanoj under the Right to Information Act (RTI) to the insurance regulator. The regulator said in its response, "The information sought is not furnished as the same would impede the process of investigation or apprehension." ET has seen IRDAI's response to the RTI query.

Care Health had allotted stock options worth ₹250 crore to Saluja, representing approximately 2.5% of the unlisted insurer's shareholding. InGovern said stock options were issued with an exercise price of ₹45.32 per share in January 2022, while in the same year, a rights issue of CARE shares was priced at ₹110 per share.

Kanoj had filed an RTI query dated April 9, 2024, with IRDAI. In its response, the regulator said Care had sought its approval to grant to Saluja on December 31, 2021. IRDAI said it had rejected this request from Care. Yet, the health insurance company allotted the stock options to Saluja.

Email queries to IRDAI and spokesperson went unanswered till Wednesday press time.

InGovern said Religare did not seek shareholder approval for the allotment of Care shares to Saluja, and there was no disclosure of this matter.

Earlier, the Burman family, which is the largest shareholder of Religare Enterprises, alleged that 22.7 million options in Care have been illegally issued to Saluja.

Burmans, promoters of , and Religare's board led by Saluja are locked in a dispute with both sides accusing each other of violating rules on corporate governance and insider trading.

On October 18, independent directors of Religare wrote a letter to regulators, including the Reserve Bank of India, Sebi, and the insurance watchdog, levelling allegations of fraud and other breaches against the Burmans.


Source: Stocks-Markets-Economic Times

Останні публікації
Oklo target nearly doubled at Wedbush on AI-driven demand for nuclear energy
24.01.2025 - 18:00
Crypto markets lose steam after Trump's first policy move
24.01.2025 - 18:00
Combination of Google's TPU-DeepMind units may be worth $700 bn - DA Davidson
24.01.2025 - 18:00
British American Tobacco, Altria shares rise after menthol ban proposal dropped
24.01.2025 - 18:00
Morocco stocks higher at close of trade; Moroccan All Shares up 0.34%
24.01.2025 - 18:00
Commerzbank says no talks with UniCredit until specific proposal made
24.01.2025 - 18:00
Venture Global aims for $64 billion valuation at debut in test for energy IPOs
24.01.2025 - 18:00
Intuitive Machines stock surges on NASA contract award
24.01.2025 - 18:00
International Paper's $7.2 billion acquisition of DS Smith gets EU approval
24.01.2025 - 18:00
Short-term stock optimism soars among retail investors, AAII survey shows
24.01.2025 - 18:00
Venture Global shares likely to open up to 6% above IPO price
24.01.2025 - 18:00
Intuitive Surgical, American Express Stir Friday's Market Cap Stock Movers
24.01.2025 - 18:00
BMW joins Chinese EV makers in filing EU court challenge to tariffs
24.01.2025 - 18:00
Turkey stocks lower at close of trade; BIST 100 down 0.08%
24.01.2025 - 18:00
Diageo stock jumps on possible Guinness sale
24.01.2025 - 18:00

© Analytic DC. All Rights Reserved.

new
Аналіз ринку Як вплине завтра звіт NFP на курс долара США?